Julie Schneider to United States Food and Drug Administration
This is a "connection" page, showing publications Julie Schneider has written about United States Food and Drug Administration.
Connection Strength
0.047
-
Off-label use of aducanumab for cerebral amyloid angiopathy. Lancet Neurol. 2021 08; 20(8):596-597.
Score: 0.047
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.